Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHP616
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
SHP616 was an investigational subcutaneous C1 esterase inhibitor (C1 INH) liquid for injection developed by Shire (later acquired by Takeda) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE). The therapy was designed to restore the levels and activity of C1-inhibitor protein, which helps regulate bradykinin signaling and ultimately reduce the risk of swelling attacks in HAE patients. It was evaluated in the Phase 3 SAHARA trial, which met its primary and key secondary endpoints, showing a significant reduction in HAE attack rate compared to placebo. Despite promising results, development was discontinued in 2019.
- Brand names
- BerinertCinryzeHaegarda
- Other names
- human C1-esterase inhibitorC1-INHC-1-INHC 1-INHplasma-derived C1-esterase inhibitor
02
Targets
C1R (Complement component 1r subcomponent)C1S (Complement component 1s subcomponent serine protease)SELE (E-selectin)FXIIa (Coagulation Factor XIIa)SELP (P-selectin)KLKB1 (Plasma kallikrein)SERPING1 (Serpin family G member 1)
Beyond the preview
Go deeper on SHP616.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHP616.